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Background: The association between the objective response to
chemotherapy and survival has not yet been fully evaluated using
large cohorts in advanced non-small cell lung cancer.
Methods: We searched for phase III trials conducted between 1991
and 2006 to investigate the role of systemic chemotherapy for
advanced non-small cell lung cancer. Associations were tested by
multiple regression analysis.
Results: Of the 1255 trials screened, 143 met our criteria, involving
50,569 patients with 309 chemotherapy regimens. In the first-line
setting, the median intention-to-treat objective response rate (ORR)
and disease control rate (DCR) were 26.4% and 62.5%, respectively
(43,551 randomized patients; 290 trials). The median of the median
survival time (MST) was 8.5 months in the first-line setting, and
both the ORR and DCR were significantly associated with the MST
in the multivariate analysis (regression coefficient  0.0788 [p 
0.0001] and 0.0794 [p  0.0001], respectively). Subgroup analysis
showed no correlation between the ORR and MST in patients
receiving chemotherapy containing molecular-targeted agents (p 
0.3817). In the second-line or later setting, the median ORR was
only 6.8%, whereas the median DCR was 42.4% (4318 randomized
patients; 19 trials). The median MST (6.6 months) was not associ-
ated with the ORR (p  0.6992), but was associated with the DCR
(p  0.0129), despite the small sample size.
Conclusions:We found that survival was associated with both the
ORR and DCR in the first-line setting, although it should be
interpreted cautiously because of the abstracted data–based anal-
ysis. Regarding chemotherapy regimens containing molecular-
targeted agents and salvage chemotherapy regimens, further
assessments are warranted to clarify the association between the
parameters.
Key Words: Lung cancer, Phase III trial, Objective response rate,
Disease control rate, Survival.
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The treatment outcome in patients with advanced non-small cell lung cancer (NSCLC) has recently improved
with advances in systemic chemotherapy; newer cytotoxic
agents have been clinically introduced since the early 1990s
and were proven, in terms of the overall patient survival, to be
superior to the older agents in the first-line setting.1 Some of
these agents have also been shown to produce survival
prolongation in the second-line setting.2,3 In addition, molec-
ular-targeted agents, acting on the specific molecule that
contributes to tumor proliferation and survival, have also
been developed; they were initially designed to be cytostatic
agents that are not so much expected to shrink tumors,4,5
although some of them have already been shown to yield
survival advantage in phase III trials.6
However, despite all these developments, the relation
between tumor response and survival duration in solid tumors
is still unclear both in clinical trials and in the individual
patient. Indeed, a close relationship between the objective
response rate (ORR) and survival has only been shown for
some advanced cancers including breast and colon cancers by
studies reviewing phase III trials.7,8 In contrast, there have
also been few studies addressing this association in patients
with advanced NSCLC, using only relatively small cohorts.9
In this paper, we address this issue for patients of advanced
NSCLC by reviewing more recent data sets from larger
patient cohorts accumulated from recent randomized phase
III trials, where both the surrogate marker (objective re-
sponse) and the clinical end point of interest (overall survival)
have been measured.
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In general, in advanced NSCLC, the ORRs to chemo-
therapeutic agents in the second-line or later setting are lower
than those in the first-line setting in cases of advanced
NSCLC.10,11 Indeed, single-agent docetaxel, considered as
the standard regimen for second-line therapy, yielded an
ORR of only 6%, even though it was proven to yield a
significant survival advantage.2 In contrast, 43% of patients
achieved stable disease. These findings might indicate that
not only tumor shrinkage, but also disease stabilization,
which is not reflected in the traditional ORR, could contribute
to survival benefit in the second-line or later settings. In this
situation, one might doubt whether tumor shrinkage would
have the same value in the second-line or later settings as in
the first-line setting. Thus, in this study, we evaluated the
association between the ORR and patient survival separately
for first-line chemotherapy and second-line or later chemo-
therapy. Additionally, we assessed the influence of both
tumor shrinkage and disease stabilization on patient survival.
PATIENTS AND METHODS
Search for Trials
We conducted a search for trials reported between
1991 and early 2006. To avoid publication bias, both
published and unpublished trials were identified through a
computer-based search of the PubMed database and abstracts
from the 10 past conferences of the American Society of
Clinical Oncology (the abstracts reported before 1996 were
not accessible on Web site). We conducted the search using
the following search terms: “lung neoplasm,” “carcinoma,”
“non-small cell,” “chemotherapy,” and “randomized con-
trolled trial.” The search was also guided by thorough exam-
ination of reference lists of original articles, review articles,
and relevant books, and of the Physician Data Query registry
of clinical trials.
Selection of Trials
Phase III trials were eligible if they compared systemic
chemotherapy regimens that contained cytotoxic agents or
molecular-targeted agents for advanced NSCLC. Trials that
investigated only immunotherapy regimens were excluded
from our analysis. Trials initially designed to assess com-
bined treatment modalities including radiotherapy and sur-
gery were also considered to be ineligible.
Data Abstraction
To avoid bias in the data abstraction process, two
observers (K.H. and Y.F.) independently abstracted the data
from the trials and subsequently compared the results. Of the
trials that met the aforementioned criteria, data were ab-
stracted from only chemotherapy regimens (but not the best
supportive care–alone arm) for this study. The following
information was obtained from each report (per treatment
regimen): number of patients enrolled and randomized, me-
dian age, proportion with poor performance status (2),
female gender and stage IV disease, chemotherapy regimen,
number of patients with objective response and stable disease
(no change), and median survival time (MST). Docetaxel,
paclitaxel, vinorelbine, gemcitabine, and irinotecan were de-
fined as new chemotherapeutic agents.12 Drugs believed to
act on known molecular targets, such as tyrosine kinase
inhibitors, antibodies to specific receptors, matrix metallopro-
teinase inhibitors, and antisense oligonucleotide, were de-
fined as molecular-targeted agents.13 Additionally, disease
control was defined as the best tumor response of complete
response, partial response, or stable disease (no change).14 All
the data were checked for internal consistency, and disagree-
ments were resolved by discussion among the investigators.
Quantitative Data Synthesis
The association between the ORR and disease control
rate (DCR) and MST was assessed using simple regression
analysis. Multiple stepwise regression analysis (with stepping
method criteria: probability of F to enter 0.05 and remove
0.10) was also performed to determine whether the ORR
and DCR each independently influenced the survival of the
patients with advanced NSCLC enrolled in the phase III
studies, after adjustment for the following possible confound-
ers: number of randomly assigned patients, median age of the
patients, proportion with poor performance status, female
gender, and stage IV disease. All p values corresponded with
two-sided tests, and significance was set at a p value of less
than 0.05.
RESULTS
Trial Flow and Characteristics of the Eligible
Trials and Chemotherapy Regimens
The flow chart of our study is shown in Figure 1. There
were 148 potentially appropriate trials, of which five were
excluded from our analysis because we were unable to obtain
any relevant data from them. Finally, 143 trials involving
50,569 enrolled patients and 309 chemotherapy regimens
fulfilled the eligibility criteria for inclusion in our analysis. Of
the total number of patients, 47,869 were randomly allocated
to chemotherapy regimens (43,551 patients to 290 regimens
and 4,318 patients to 19 regimens in the first-line setting and
FIGURE 1. A flow chart of the progress of trials through
the review.
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second-line or later setting, respectively). The baseline char-
acteristics of the 143 trials are shown in Table 1. Most trials
had two treatment regimens and low proportions of patients
with poor performance status and female patients. The de-
mographics of the 309 chemotherapy regimens are also listed
in Table 2. In the first-line setting, cisplatin-based chemo-
therapy was the most frequently investigated (167 regimens;
58%). Molecular-targeted agents were assessed in 10 regi-
mens (3%), all of them in combination with cytotoxic che-
motherapeutic agents. Conversely, in the second-line or later
settings, cisplatin-based chemotherapy was not investigated
at all and newer agent monotherapy was the most frequently
evaluated (13 regimens; 68%).
Associations between the ORR and DCR and
MST in Patients Receiving First-Line
Chemotherapy Regimens
In the first-line setting, based on intention-to-treat anal-
ysis using all randomized patients, the median ORR and DCR
were 26.4% (range, 0–59.0%) and 62.5% (range, 14.%–
94.3%), respectively. Cisplatin-based chemotherapy yielded
a median ORR of 28.0%, which rose slightly to 30.4% when
cisplatin was combined with newer agents. The overall me-
dian MST of patients receiving first-line chemotherapy was
8.5 months (range, 3.8–14.8 months), and the ORR was signif-
icantly associated with the MST (p  0.0001; Figure 2A).
Subgroup analysis showed the close association be-
tween these parameters for the 61 combination chemotherapy
regimens of cisplatin plus newer agents, one of the current
standard treatments (p  0.0436). However, there was no
significant correlation between the ORR and MST for mo-
lecular-targeted agents (3838 randomized patients with 10
regimens; p  0.3817), even though all these agents were
combined with platinum-containing regimens.
Regarding the DCR, we found a significant correlation
between its rate and the MST in the first-line chemotherapy
regimens (p  0.0001; Figure 2B). Multiple linear regression
analysis revealed that the ORR and DCR were each inde-
pendently associated with the MST, even after adjustment
for the various possible confounders (regression coefficients 
0.0788; p 0.0001 and 0.0794; p 0.0001, respectively). In
this model, the MST was also affected by both proportion of
patients with poor performance status (p  0.0001).
Associations between the ORR and DCR and
MST in Patients Receiving Second-Line or Later
Chemotherapy Regimens (Salvage Regimens)
In the second-line or later setting (salvage setting), data
on the ORR were available for all 19 regimens. The median
intention-to-treat ORR was only 6.8% (range, 0.8%–12.2%),
whereas the median DCR was 42.4% (range, 30.9%–58.5%).
The median MST was 6.6 months (range, 5.4–10.2 months)
and showed no correlation with the ORR (p 0.6992, Figure
3A). In contrast, the DCR was better associated with the MST
despite the small sample size (p  0.0129, Figure 3B).
DISCUSSION
We found a positive association between the ORR and
MST based on the abstracted data obtained from clinical trials
of advanced NSCLC evaluating newer chemotherapeutic
agents in the first-line setting. A similar study was also
conducted in 1998 using a smaller cohort. It demonstrated a
significant correlation between the ORR and MST, although
only single-agent chemotherapy regimens were assessed, and
both first-line chemotherapy and second-line chemotherapy
were investigated together.9 Their results and ours might
support the hypothesis that the achievement of an objective
response is associated with a true survival benefit even in
patients of advanced NSCLC that is only moderately chemo-
sensitive.
In this study, we used data collected in phase III trials
not phase II trials because phase III trials involve very large
data sets of patients. These trials also accurately measure the
key clinical endpoint, namely, the overall survival, in addi-
tion to evaluation of the major surrogate marker, that is, the
objective response.15 However, our results must be inter-
preted with caution because the ORRs in phase III trials are
not always similar to those in phase II trials, in which tumor
shrinkage is exactly assessed as a surrogate marker.16 One
can also argue that the ORR data from phase III trials are less
reliable than those of phase II trials because of the annotation
with the major response criteria that confirmation of changes
in tumor size may not be part of the standard practice in
protocols where overall survival is evaluated as the key
endpoint.17 However, it was recently reported that confirma-
tion of responses did not seem to add any value to response
TABLE 1. Demographics of the 143 Trials (per Trial)
First-line Second-line or Later Total
Total no. of trials 133 10 143
Total no. of randomized patients 43,551 4,318 47,869
Median no. of randomly assigned patients (range) 247 (24–1218) 316 (104–1129) 259 (24–1218)
Publication type (full text/abstract form only) 117/16 8/2 125/18
No. of chemotherapy regimens (2/3/4) 105/22/6 9/1/0 114/23/6
% of patients with poor PS (median, range) 19 (0–100) 33 (0–35) 19 (0–100)
% of female patients, median (range) 24 (3–80) 28 (9–35) 24 (3–80)
% of pts with stage IV disease, median (range) 67 (27–100) 77 (48–89) 67 (27–100)
PS, performance status.
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assessment based on the first best response observed.18 Thus,
this issue might only minimally affect our results, although
further studies may be required.
In contrast to the case for first-line chemotherapy, we
failed to find any clear association between the ORR and
survival after second-line or later chemotherapy for relapsed
NSCLC (p  0.6992). In contrast, the MST correlated with
the DCR (p  0.0129). In this setting, chemotherapeutic
agents could generally be expected to bring about disease
stabilization rather than tumor shrinkage. It has been pro-
posed that the proportion of patients whose best response is
progressive disease may be a surrogate marker that seems to
reflect the DCR, complete response, partial response, or
stable disease (no change).14,19 The association between this
progressive disease rate and the MST was also investigated in
42 first- and second-line single-agent phase II trials of
NSCLC, and the progressive disease rate indeed correlated
closely with the MST.20 Similar to this impact of progressive
disease rate on patient survival, we also found an association
between the DCR and MST with the larger data set. These
suggest that the DCR might be a good candidate for one of the
surrogate markers for novel types of anticancer agents both in
the first-line and second-line or later settings, although the
second-line data were more heterogeneous and smaller.
In regard to molecular-targeted agents, the majority
usually do not produce any significant tumor shrinkage.13
TABLE 2. Chemotherapy Regimens and Outcomes (per Chemotherapy Regimen)
No. of
Treatment
Arms
No. of
Randomized
pts.
CR Rate (%),
Median (range)
PR Rate (%),
Median (range)
OR Rate (%),
Median (range)
DC Rate (%),
Median (range)
MST (mo),
Median (range)
First-line chemotherapy
Total no. of chemotherapy
regimens
290 43,551 0.9 (0–13.6) 24.3 (0–53.8) 26.4 (0–59.0) 62.5 (14.3–94.3) 8.5 (3.8–14.8)
Platinum-based regimens
Cisplatin-based
Cisplatin monotherapy 7 1194 0.4 (0–2.8) 11.1 (6.3–12.4) 11.3 (6.7–13.9) 46.4 (31.9–85.0) 6.9 (5.3–9.1)
Cisplatin  new agents
combinations
61 10,685 1.3 (0–5.8) 30.2 (12.1–45.4) 30.4 (13.0–47.2) 64.3 (37.0–79.8) 9.6 (6.3–14.8)
Cisplatin  other (older)
agents
99 9820 1.0 (0–9.3) 25.0 (5.4–53.8) 27.1 (7.6–59.0) 68.3 (33.1–94.3) 8.0 (4.9–12.0)
Other platinum-based
Carboplatin-based
combinations
43 9616 1.2 (0–6.1) 27.1 (7.9–43.4) 28.3 (7.9–45.0) 67.4 (38.8–84.8) 9.0 (6.6–12.3)
Others 1 70 0 11.4 11.4 70.0 8.9
Nonplatinum regimens
Regimens containing newer
agents
Monotherapy 24 3101 0.3 (0–2.2) 14.5 (5.7–41.1) 15.5 (5.7–41.1) 47.5 (14.3–90.4) 7.1 (4.2–14.3)
Combination therapy 22 3806 1.0 (0–4.3) 27.6 (9.2–37.2) 27.4 (9.2–41.0) 57.2 (31.2–72.6) 8.7 (6.7–11.5)
Regimens containing
other (older) agents
23 1421 0 (0–13.6) 17.6 (0–37.9) 17.6 (0–51.5) 53.6 (28.1–75.7) 6.8 (3.8–10.2)
Molecular-targeted agents (with
cytotoxic chemotherapy)
EGFR-TKI containing 6 2494 1.9 (0.6–3.0) 30.0 (27.8–44.1) 31.0 (21.5–47.1) 56.1 9.9 (8.7–10.6)
Other combinations 4 1344 1.1 (0.9–1.2) 22.8 (21.2–23.8) 24.3 (22.4–25.8) 58.4 (53.2–63.5) 10.8 (8.6–12.5)
Second-line chemotherapy or
later settings
Total no. of chemotherapy
regimens
19 4318 0.1 (0–6.1) 6.2 (0.8–10.4) 6.8 (0.8–12.2) 42.4 (30.9–58.5) 6.6 (5.4–10.2)
Nonplatinum regimens
Regimens containing newer
agents
Monotherapy 13 1816 0.5 (0–6.1) 6.1 (2.7–10.4) 8.3 (2.7–12.2) 42.7 (31.3–58.2) 7.1 (5.4–10.1)
Combination therapy 1 65 0 6.2 6.2 58.5 10.2
Regimens containing other
(older) agents
Monotherapy 3 820 0 (0–0) 2.7 (0.8–4.6) 4.6 (0.8–8.5) 31.1 (30.9–31.4) 6.5 (5.6–8.3)
Molecular-targeted agents (with
cytotoxic chemotherapy)
EGFR-TKI-containinga 2 1617 0.35b 7.0b 7.3b 36.5b 6.2b
a Monotherapy with tyrosine kinase inhibitor. b Mean scores. CR, complete response; PR, partial response; OR, objective response; DC, disease control; MST, median survival
time; EGFR-TKI, epidermal growth factor receptor–tyrosine kinase inhibitor.
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Many investigators agree that objective response can no
longer be considered as an accurate surrogate marker for
molecular-targeted agents.21 Rather, the efficacy data ob-
tained when these agents are combined with other chemo-
therapeutic agents have generally been considered to be
helpful for defining the potential efficacy of molecular-tar-
geted agents.13 However, we failed to find that the objective
response to such combination regimens was associated with
patient survival, which suggests that this methodology might
not be sufficiently sensitive for accurate determination of the
subtle effects of these compounds. The limitation in our study
was that the number of trials involving molecular-targeted
agents that were included in the study was obviously limited.
We also assessed the association between the ORR and
patient survival in the first-line setting for all molecular-
targeted agents together, although these agents have diverse
mechanisms of action.4 Thus, further investigation including
more relevant trials are warranted to confirm whether data
from combination chemotherapy would be useful.
Several major limitations should be discussed; we dealt
with mostly negative and very heterogeneous trials, limiting
our conclusions. Additionally, although the MST is the most
frequently reported indicator as survival data, this parameter
has not yet proven to represent the entire benefit from
chemotherapy. All our analyses were based on abstracted
data and not individual patient data (IPD). An IPD-based
analysis could be a more appropriate statistical design to
assess the relationship between the ORR and DCR and
survival and must be strongly considered in a future study.
Furthermore, the response criteria varied among the trials
reviewed by us, mainly between World Health Organization
criteria and Response Evaluation Criteria in Solid Tumors.
However, this factor seems unlikely to have significantly
affected our key results because there are few differences
between these two sets of criteria in terms of validity in
relation to tumor volume and intercriteria reproducibility in
NSCLC patients.22
In conclusion, our data might support the hypothesis
that the achievement of an objective response to first-line
chemotherapy in advanced NSCLC patients is associated
with a true survival benefit, although an IPD-based meta-
analysis would be strongly needed to confirm it. Despite the
several limitations of our study, our data reveal critical points
that must be evaluated in future studies. Conversely, for
treatment situations that are less expected to bring about
tumor shrinkage, including assessment of molecular-targeted
agents or chemotherapy in the second-line or later settings, it
might be desirable to develop alternative surrogate markers.
Further assessments are warranted to clarify the associations
between the ORR and DCR and patient outcome, especially
in such regimens.
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